In 2023, the total market for generic drugs worldwide was estimated at around 424 billion U.S. dollars. The market is expected to increase to more than 600 billion U.S. dollars by the begin of the next decade. This statistic illustrates a forecast for the total market of generic drugs worldwide.

Global Generic Pharmaceuticals market size is expected to reach $666.48 billion by 2029 at 7.9%, segmented as by type, biosimilars, generics

The Generic Pharmaceuticals Market was USD 346.5 bn. It is expected to reach USD 740.5 bn in 2032 at a CAGR of 8.1% from 2023-2032.

Generic pharmaceuticals account for nearly three-fourths of all prescription drugs dispensed yearly in Canada. Generic pharmaceutical manufacturers are critical to this supply and have an invaluable role in public health and saving patients and insurers millions. Rapid population growth, rising incomes and a growing population of over 65 in Canada in recent years have also contributed to jumps in prescription spending. Despite this importance, the industry's revenue growth hinges on federal and provincial pricing policies, brand name patent expirations and competition from imports and other domestic manufacturers. In the last five years, revenue has dropped at a CAGR of 4.9% to an estimated $3.0 billion, with an expected growth of 0.1% in 2025. Growing pricing pressures have been one of the largest challenges faced by generic manufacturers for over a decade. Many measures regulate what generic pharma producers can charge for drugs, with the exact cost of a generic dependent on how many different companies are selling similar options. These stringent pricing policies have made it extremely difficult for manufacturers to efficiently manage cost pressures, like recent inflation, labour challenges and other operational pressures. While pricing policies have slightly adjusted to account for inflation, generic pharma producers link a lack of flexibility to raise prices to lower profit. Canada's use of generic prescription drugs will remain strong, but some challenges could hurt manufacturers' ability to strengthen profit. Competitive pressures from regulatory bodies, branded competitors and lower-cost imports could weaken profit. Still, an upcoming patent cliff will create opportunities for generic manufacturers, allowing them to introduce new unbranded drugs. Regulatory support will be crucial to reduce import reliance and shorten supply chains, potentially through tax incentives, subsidies and streamlined pathways to expand local manufacturing. A significant area of influence is the fate of the CUSMA, and whether or not President Trump's tariffs will impact the flow of pharmaceuticals between the US and Canada. Trade barriers introduce massive uncertainties for the economies of both countries and substantial disruptions to established supply chains. While the situation is evolving, manufacturers are responding by seeking alternative trade partnerships or enhancing existing relationships with other countries to mitigate these risks. Revenue is expected to grow at a CAGR of 1.1% to an estimated $3.1 billion over the next five years.

The share of generics in the respective pharmaceutical market in Portugal saw no significant changes in 2022 in comparison to the previous year 2021 and remained at around **** percent of sales value (turnover) in the same market. Still, the share reached its highest value in the observed period in 2022. Find more key insights for the share of generics in the respective pharmaceutical market in countries like France, Norway, and Czechia.

The share of generics in the respective pharmaceutical market in Switzerland increased by 0.3 percent of sales value (turnover) in the same market (+1.62 percent) in 2022. With 18.8 percent of sales value (turnover) in the same market, the share thereby reached its highest value in the observed period. Find more statistics on other topics about Switzerland with key insights such as share of generics in the pharmaceutical market and value of pharmaceutical sales.

The Report Covers the Global Generic Drug Market is Segmented By Therapeutic Area (Cardiovascular, CNS, Antibiotics, Oncology, Gastrointestinal, Hormones, Pain Management, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Region Forecast 2019-2030. Key Players covered in this report are Mylan N.V. (U.S.), Sun Pharmaceutical Industries Limited (India), Teva Pharmaceutical Industries, Ltd. (Israel), Dr Reddy’s Laboratories (India), Novartis AG (Sandoz International GmbH) (Switzerland), Apotex Holdings Inc. (Canada), Apotex Holdings Inc. (Canada), Endo International plc (U.S.), Pfizer Inc. (U.S.), Johnson & Johnson Services Inc., (Janssen Pharmaceutica) (U.S.), Lupin Limited (India), Merck & Co, Inc. (U.S.), Mitsubishi Tanabe Pharma (Japan), Momenta Pharmaceuticals (U.S.), Nexus Pharmaceuticals (U.S.), Novo Nordisk (Denmark).

Snapshot img

Generic Drugs Market Size 2025-2029

The generic drugs market size is forecast to increase by USD 217.4 billion, at a CAGR of 7.6% between 2024 and 2029.

The market is driven by the increasing demand for low-cost alternatives to branded medicines. This trend is particularly pronounced in developing economies where affordability is a significant factor in healthcare access. However, the market faces challenges, including the advent of Robotic Process Automation (RPA) in the pharmaceutical industry, which could potentially reduce the cost advantage of generic drugs. Additionally, rising credibility issues related to generic drugs pose a significant challenge, as consumers and healthcare providers increasingly demand assurance of quality and safety. Companies in the market must navigate these challenges by focusing on ensuring the highest standards of quality and safety, while also leveraging technological advancements to maintain cost competitiveness.
Strategic partnerships, mergers and acquisitions, and collaborations could also provide opportunities for market expansion and growth. Overall, the market presents both opportunities and challenges, requiring a strategic approach from market participants to capitalize on the former and mitigate the latter.

What will be the Size of the Generic Drugs Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, shaped by various factors that impact its dynamics. Patient education plays a crucial role in ensuring the effective utilization of medications, with dosage forms varying from capsules to tablets and liquids. Clinical trials and pharmacokinetic studies contribute to regulatory approval, ensuring therapeutic equivalence and drug safety. Pharmaceutical manufacturing involves GMP compliance and stability testing to maintain quality, while patent expiration triggers increased competition and price reductions. Drug interactions necessitate diligent monitoring and education, with regulatory bodies such as the EMA and FDA overseeing approvals. Value-based healthcare and market access strategies prioritize cost-effectiveness analysis, influencing pricing and distribution channels.

Online pharmacies and retail pharmacies adapt to evolving market trends, offering convenience and accessibility. Intellectual property rights and pharmacy dispensing regulations shape the competitive landscape. Bioequivalence studies and drug utilization reviews facilitate generic substitution, while pharmacy dispensing and capsule filling processes ensure accurate and efficient prescription fulfillment. The continuous unfolding of market activities necessitates ongoing attention to drug safety, regulatory compliance, and pricing strategies.

How is this Generic Drugs Industry segmented?

The generic drugs industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Route Of Administration

  Oral
  Injectables
  Topical
  Inhalers


Type

  Small-molecule generics
  Biosimilars


Application

  Anti-infectives
  CNS
  Others


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

.

By Route Of Administration Insights

The oral segment is estimated to witness significant growth during the forecast period

The oral route of administration is the most commonly used. Oral administration is the ingestion of a drug through the mouth into the gastrointestinal tract. The oral drug delivery system market segment includes drugs that can be administered in the form of capsules, tablets, syrups, solutions, and suspensions. The growth of the segment is accelerating at a moderate pace due to the ease of usage and an increasing number of companies investing in research and development for oral treatment. The advantages provided by the oral route, such as better availability, rapid drug delivery, and high efficacy, are further expected to propel the growth of the oral segment, which, in turn, will drive the growth of the market during the forecast period.

Request Free Sample

The Oral segment was valued at USD 232.00 billion in 2019 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 33% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Request Free Sample

The market in North America is experiencing significant growth,

Global super generics market size is expected to grow from USD 84 billion in 2024 to USD 91 billion in 2025 and USD 200 billion by 2035, at a CAGR of 8.2%

The market for copied brand-named drugs, the so-called generic pharmaceuticals, has been increasing in Norway for years. In 2023, generic pharmaceuticals composed over 55 percent of the total pharmaceutical market volume in the country.  Large share of expired patents   A generic drug contains the same chemical substance as an original, previously patented, brand-named drug, and can enter the market first when the patent of the original drug has expired. In 2018, for the first time the larger share of pharmaceutical sales based on volume in Norway came from drugs whose patents were expired, and a large part even from drugs whose patent expired 40 years ago or longer. The whole pharmaceutical market in Norway is growing    The sales value of the total pharmaceutical market has been increasing since 2000. In 2023, the market reached the highest sales value, amounting to over 37 billion Norwegian kroner. That was more than twice the sales value of 2010.

Egypt Generics Drugs Market was valued at USD 1275.34 Million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.07% through 2029.

Generic Drug Market Outlook

According to our latest research, the global generic drug market size reached USD 438.6 billion in 2024, reflecting robust demand for cost-effective pharmaceutical solutions. The market is expected to expand at a CAGR of 6.8% from 2025 to 2033, with the total market value projected to reach USD 849.2 billion by 2033. This impressive growth is primarily attributed to the escalating prevalence of chronic diseases, rising healthcare expenditures, and the increasing expiration of branded drug patents, which collectively drive the adoption of generic alternatives worldwide.

The growth trajectory of the generic drug market is underpinned by several critical factors. First and foremost, the rising incidence of chronic and lifestyle-related diseases, such as cardiovascular disorders, diabetes, and cancer, is fueling consistent demand for affordable medications. As healthcare systems globally grapple with cost-containment pressures, generic drugs offer a viable solution by providing equivalent therapeutic efficacy at a fraction of the cost of branded drugs. Additionally, the growing geriatric population, which is more susceptible to chronic conditions, further amplifies the demand for generic pharmaceuticals. Governments and insurance providers are increasingly encouraging the use of generics to control healthcare budgets, creating a favorable regulatory environment that accelerates market expansion.

Another significant growth driver is the patent cliff phenomenon, where a substantial number of blockbuster drugs are losing patent protection over the coming years. This scenario presents lucrative opportunities for generic drug manufacturers to introduce cost-effective alternatives, thereby enhancing their market presence. Technological advancements in drug formulation and manufacturing processes have also contributed to the rapid proliferation of high-quality generics. Furthermore, strategic collaborations, mergers, and acquisitions among leading pharmaceutical companies are facilitating the entry of new generic products into the market, ensuring a steady pipeline of offerings to meet diverse therapeutic needs.

The increasing focus on healthcare accessibility, especially in emerging economies, is another pivotal factor propelling the growth of the generic drug market. Governments in Asia Pacific, Latin America, and parts of Africa are implementing policies aimed at improving access to essential medicines, which often include generics. International organizations and non-governmental agencies are also playing a crucial role in promoting generic drug adoption through various health initiatives. These efforts are complemented by rising awareness among patients and healthcare professionals regarding the safety, efficacy, and cost benefits of generics, further bolstering market growth.

From a regional perspective, Asia Pacific stands out as the fastest-growing market, driven by large patient populations, increasing healthcare investments, and expanding pharmaceutical manufacturing capabilities. North America and Europe continue to dominate the global landscape, owing to well-established regulatory frameworks, high healthcare expenditures, and rapid uptake of generic medications. Meanwhile, Latin America and the Middle East & Africa are witnessing steady growth, supported by improving healthcare infrastructure and proactive government initiatives to promote generic drug usage. The regional diversity in market dynamics highlights the global relevance and resilience of the generic drug industry.

Product Type Analysis

The generic drug market is segmented by product type into simple generics, super generics, and biosimilars, each contributing uniquely to the overall market expansion. Simple generics represent the largest share, owing to their straightforward manufacturing processes and widespread acceptance as substitutes for branded drugs. These drugs are chemically identical to their branded counterparts and offer the same therapeutic outcomes, ma

Introduction

Global Generic Drugs Market size is expected to be worth around US$ 691 Billion by 2033 from US$ 424.2 Billion in 2023, growing at a CAGR of 5.0% during the forecast period from 2024 to 2033. In 2023, North America led the market, achieving over 38.4% share with a revenue of US$ 162.8 Billion.

This growth is primarily fueled by the increasing demand for cost-effective medications, the expiration of patents on blockbuster drugs, and government policies encouraging the adoption of generic drugs. The rising prevalence of chronic diseases, along with escalating healthcare needs in developing regions, also plays a significant role in driving market expansion. Furthermore, enhanced manufacturing capabilities and expanding distribution networks are key contributors to this robust growth.

Generic drugs are bioequivalent alternatives to brand-name medications, offering the same active ingredients, dosage forms, strengths, quality, safety, and efficacy. Examples include ibuprofen, metformin, and simvastatin. These drugs become available after the expiration of patents on brand-name drugs and are approved by regulatory authorities. Offering affordability, generic drugs are essential for managing chronic conditions such as hypertension, diabetes, infections, and cardiovascular diseases. They are especially beneficial for patients without comprehensive insurance coverage or those dealing with high medical costs.

The market’s growth is driven by the increasing demand for generics due to the patent expirations of brand-name drugs. Rising global healthcare costs also provide a favorable environment for market expansion. Additionally, the aging population, which is more prone to chronic illnesses like cardiovascular diseases, diabetes, and respiratory disorders, is fueling demand. Collaborations among leading pharmaceutical companies to enhance generic drug production and the integration of advanced technologies for developing complex generics with specialized formulations further bolster market growth.

BCC Research Market Analyst says global market for generic drugs is expected to grow from $435.3 billion in 2023 and projected to reach $655.8 billion by the end of 2028, at a CAGR of 8.5%.

The United States generic drug market reached a value of about USD 163.68 Billion in 2024. The market is further expected to grow at a CAGR of 12.00% in the forecast period of 2025-2034 to reach a value of approximately USD 508.37 Billion by 2034.

Generic pharmaceuticals account for nine of every ten prescription drugs dispensed yearly. Generic pharmaceutical manufacturers are central to this supply and have an invaluable role in public health and saving patients and insurers billions. Despite this importance, the industry's revenue growth hinges on patent expirations, FDA approvals of new drug applications and competition from foreign companies and other domestic producers. In the last five years, revenue has been expanding at a CAGR of 0.9% to an estimated $50.3 billion, including expected growth of 3.9% in 2025. Maintaining prices at acceptable levels has been a significant challenge for additional revenue growth. Generic pharmaceutical manufacturers are grappling with fierce competition and steep pricing pressures, as buyers only base their decisions on price, a result of the lack of differentiation in products. This has driven generic drug prices down to levels that barely cover production costs, leading to closures and bankruptcies among domestic manufacturers. Teva, the largest global generic producer, has also struggled with generics' low prices. The company is restructuring its generics business by shifting focus to complex generics and scaling back the production of certain drugs. Downward pressure on prices will keep revenue growth moderate moving forward despite tailwinds that will support generic drug use. Spending on prescription drugs won't slow as the number of over-65 adults and the rate of chronic illness increase. A patent cliff will allow generic manufacturers to introduce new unbranded drugs to the market, with the growth of the biosimilar market supporting demand for new, affordable generics. However, navigating the environment of tariffs will present challenges for the pharmaceutical supply chain by potentially increasing costs and causing delays. Tariff-related issues could also complicate recent trends in offshoring production, as companies may need to reassess their sourcing and manufacturing strategies to maintain efficiency and cost-effectiveness. Revenue is expected to continue rising, albeit marginally, at a CAGR of 0.9% to an estimated $52.6 billion.

Saudi Arabia Generic Drugs Market was valued at USD 7.41 billion in 2023 and is expected to reach USD 9.92 billion by 2029 with a CAGR of 5.12% during the forecast period.

The Generic Pharmaceuticals Market size was valued at USD 391.5 billion in 2023 and is projected to reach USD 684.12 billion by 2032, exhibiting a CAGR of 8.3 % during the forecasts period. A generic product is a drug that is chemically similar to the branded product but is produced after the expiration of the patent on the branded drug. These generics are bioequivalent to the brand-name drugs in terms of active ingredients, dosage form, strength, and route of administration. Other features of generic pharmaceuticals include the fact that they are cheaper than brand-name drugs because many manufacturers can produce them once the patent has expired. Before being approved for use, they have to go through several tests by regulatory bodies to determine their safety, efficacy, and bioequivalence to the reference drug. Benefits of generic drugs relate to the greater availability and cost of basic medicines, which can contribute to health care cost savings for clients and health facilities. It gives consumers more choices and opportunities while helping them achieve higher quality and efficiency than regulatory authorities set.

The global generic drugs market was valued at USD 370.30 Billion in 2024, driven by the rising incidence of chronic diseases along with increasing drug approvals across the globe. The market is expected to grow at a CAGR of 6.80% during the forecast period of 2025-2034, with the values likely to reach USD 714.93 Billion by 2034.

In recent years, generic medications are becoming increasingly popular in Italy. As a matter of fact, the market volume share of generics steadily grew over time. In 2022, generics accounted for **** percent of the total pharmaceutical market volume.   Consumption of generic medication The use of generic medication was mainly common in some Northern Italian regions such as Lombardy, Friuli-Venezia Giulia and the Autonomous Province of Trento. People living in the South and in the Center were less likely to take generic medication. Calabria was the region with the lowest share of consumption of generic drugs. Likewise, the incidence of generics on public pharmaceutical expenditure was higher in northern than in southern regions.   Growth rate of the generic pharmaceutical market“  Between 2017 and 2019, the market of generics kept on increasing in terms of both volume and value, before experiencing a contraction in 2020. In regard to volume, the worst performing quarter was the second of 2020, when the market of generic drugs decreased by **** percent. The same quarter proved to be hard with reference to value too, with revenue experiencing a contraction of *** percent.